Scienza e Tecnologia
Anjarium Biosciences Raises CHF 55.5M ($61M) Series A Financing to Develop Next-Generation Non-viral Gene Therapies
-
ZURICH , Sept. 16, 2021 /PRNewswire/ -- Anjarium Biosciences AG ("Anjarium"), a biotech company focused on creating and delivering a new class of non-viral gene therapies today announced the closing of a CHF55.5M ( $61M ) Series A financing. The round was co-led by Abingworth and Gimv, with significant participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company).
Anjarium's innovative approach leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology and nanoparticle engineering to rationally design and produce tissue-targeted gene therapies, optimized to improve patient outcomes in a range of serious genetic diseases.
The Company's unique platform combines proprietary DNA-based gene vectors, natural and synthetic nanoparticle delivery modalities – including its novel Hybridosome™ technology – and cost-efficient, scalable manufacturing solutions.
Through this approach Anjarium has the potential to deliver more predictable, lasting, and inclusionary ways to tackle genetic disease throughout a patient's lifetime. Further, this new class of gene therapy provides the opportunity to address key shortcomings of current viral gene therapy development by creating medicines with reduced immunogenicity, increased drug payload capacity, enhanced targeted delivery, and individualized multiple dosing.
The proceeds from the Series A financing will enable Anjarium to expand its team, advance its ground-breaking platform and progress several therapeutic pipeline programs towards clinical development.
In conjunction with Anjarium's Series A financing, Dr. Bali Muralidhar of Abingworth, Dr. Bram Vanparys of Gimv and Dr. Dina Chaya of Omega Funds will join the company's Board of Directors.
Anjarium is focused on creating a new class of non-viral gene therapies to deliver more predictable, enduring, and inclusionary ways to tackle genetic disease throughout a patient's lifetime. The Company's versatile platform aims to leverage breakthrough science and expertise at the interface of genetic medicine, synthetic biology and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies.
Investors in Anjarium include leading international and strategic investors Abingworth, Gimv, Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company). www.anjarium.com
Abingworth is a leading transatlantic life sciences investment firm. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top calibre management teams building world-class companies. Since 1973, Abingworth has invested in over 175 life science companies, leading to
45 M &As and 71 IPOs. Our therapeutic focused investments fall into three categories: seed and early-stage, development stage, and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals at offices in London , Menlo Park ( California ), and
Boston . www.abingworth.com
Gimv is a European investment company, listed on Euronext Brussels, with almost 40 years' experience in private equity and venture capital. The company currently has a portfolio of
EUR 1.1 billion of investments in around 50 portfolio companies, with combined turnover of
EUR 2.75 billion and 14,000 employees. As a recognized market leader in selected investment platforms, Gimv identifies entrepreneurial, innovative companies with high growth potential and supports them in their transformation into market leaders. Gimv's four investment platforms are Connected Consumer, Health & Care, Smart Industries and Sustainable Cities. Further information on Gimv can be found on www.gimv.com
Founded in 2004, Omega Funds is a leading international investment firm that creates and invests in life sciences companies that target our world's most urgent medical needs. Omega focuses on identifying and supporting companies through value inflection points across the full arc of innovation, from company formation through clinical milestones and commercial adoption. Omega Funds' portfolio companies have brought 39 products to market in multiple therapeutic areas, including oncology, rare diseases, precision medicine and others. Please visit www.omegafunds.com for additional information.
media@anjarium.com
Mark Swallow , George Underwood ,
Eleanor Perkin
anjarium@medistrava.com